A long-term multicenter study: Entecavir versus Tenofovir in treatment of nucleos(t)ide analogue-naive chronic hepatitis B patients.

Kayaaslan, Bircan; Akinci, Esragul; Ari, Alpay; Tufan, ZELİHA; Alpat, Saygin; Gunal, Ozgur; Tosun, Selma; Guner, Rahmet; Tabak, Fehmi

doi:10.1016/j.clinre.2017.06.008

A long-term multicenter study: Entecavir versus Tenofovir in treatment of nucleos(t)ide analogue-naive chronic hepatitis B patients.

Copy For Citation

Kayaaslan B., Akinci E., Ari A., Tufan Z., Alpat S. N., Gunal O., ...More

Clinics and research in hepatology and gastroenterology, vol.42, no.1, pp.40-47, 2018 (SCI-Expanded)

Publication Type: Article / Article
Volume: 42 Issue: 1
Publication Date: 2018
Doi Number: 10.1016/j.clinre.2017.06.008
Journal Name: Clinics and research in hepatology and gastroenterology
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.40-47
Ankara Yıldırım Beyazıt University Affiliated: No

Abstract

Background: Entecavir (ETV) and tenofovir disoproxil fumarat (TDF) are the two first-line therapies recommended in the treatment of chronic hepatitis B because of having potent antiviral effect and high genetic barriers against resistance. We aimed to compare efficacy of these drugs and to evaluate predictors of viral suppression.